Resources
NEW ENGLAND JOURNAL OF MEDICINE WHITE PAPER
In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.
The mean change in body weight from baseline to week 68 was −14.9% in the
semaglutide group as compared with −2.4% with placebo, for an estimated treatment difference of −12.4 percentage points